- 专利标题： PROCESS FOR THE PREPARATION OF 6-(CYCLOPROPANEAMIDO)-4-((2-METHOXY-3-(1-METHYL-1H-1,2,4-TRIAZOL-3-YL)PHENYL)AMINO)-N-(METHYL-D3)PYRIDAZINE-3-CARBOXAMIDE
-
申请号： US17131718申请日： 2020-12-22
-
公开(公告)号： US20210107897A1公开(公告)日： 2021-04-15
- 发明人: Ke Chen , Joerg Deerberg , Dong Lin , Michael Dummeldinger , Bahar Inankur , Sergei Kolotuchin , Jun Li , Amanda J. Rogers , Victor W. Rosso , Eric M. Simmons , Maxime C.D. Soumeillant , Daniel S. Treitler , Jianji Wang , Bin Zheng , Michael J. Smith , Neil A. Strotman , Steven Tymonko , Tamas Benkovics
- 申请人： Bristol-Myers Squibb Company
- 申请人地址： US NJ Princeton
- 专利权人： Bristol-Myers Squibb Company
- 当前专利权人： Bristol-Myers Squibb Company
- 当前专利权人地址： US NJ Princeton
- 主分类号： C07D403/12
- IPC分类号： C07D403/12 ; C07C211/09 ; C07D237/24 ; C07D249/08
摘要：
The invention relates to an improved process for synthesizing 6-(cyclopropaneamido)-4-((2-methoxy-3-(1-methyl-1H-1,2,4-triazol-3-yl)phenyl)amino)-N-(methyl-d3)pyridazine-3-carboxamide of the formula: Compound I is currently in clinical trials for the treatment of auto-immune and auto-inflammatory diseases such as psoriasis.
公开/授权文献
信息查询
